Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?
Details
Publication Year 2016-12, Volume 10, Issue #10, Page 1497-1515
Journal Title
Mol Oncol
Publication Type
Journal Article
Abstract
Histone methyltransferases (HMTs) catalyze the methylation of lysine and arginine residues on histone tails and non-histone targets. These important post-translational modifications are exquisitely regulated and affect chromatin compaction and transcriptional programs leading to diverse biological outcomes. There is accumulating evidence that genetic alterations of several HMTs impinge on oncogenic or tumor-suppressor functions and influence both cancer initiation and progression. HMTs therefore represent an opportunity for therapeutic targeting in those patients with tumors in which HMTs are dysregulated, to reverse the histone marks and transcriptional programs associated with aggressive tumor behavior. In this review, we describe the known histone methyltransferases and their emerging roles in breast cancer tumorigenesis.
Publisher
Wiley
WEHI Research Division(s)
Stem Cells And Cancer
PubMed ID
27717710
NHMRC Grants
NHMRC/1016701 NHMRC/1086727
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2016-10-19 11:52:30
Last Modified: 2017-09-29 12:04:34
An error has occurred. This application may no longer respond until reloaded. Reload 🗙